scispace - formally typeset
Open AccessJournal ArticleDOI

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Reads0
Chats0
TLDR
This AASLD 2018 Hepatitis B Guidance provides a data-supported approach to screening, prevention, diagnosis, and clinical management of patients with hepatitis B.
About
This article is published in Hepatology.The article was published on 2018-04-01 and is currently open access. It has received 2399 citations till now. The article focuses on the topics: Hepatitis B & Mass screening.

read more

Citations
More filters
Journal ArticleDOI

Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection.

TL;DR: HCAR‐T therapy is safe and effective in DLBCL and ALL patients with chronic and resolved HBV infection under proper antiviral prophylaxis andHBV infection did not affect in vivo expansion of h CAR‐T cells or increase the risk of severe cytokine release syndrome.
Journal ArticleDOI

Hepatitis B Core Antibody: Role in Clinical Practice in 2020

TL;DR: It is crucial for clinicians to understand the need to screen for hepatitis B core antigen (anti-HBc status), proper interpretation of HBV biomarkers, and that “anti- HBc only” indicates HBV exposure, lifelong persistence of cccDNA with incomplete infection control, and potential risk for reactivation.
Journal ArticleDOI

Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis.

TL;DR: In this article, the authors investigated the feasibility of APRI and FIB-4 for the longitudinal evaluation of liver fibrosis in patients with chronic hepatitis B and C. This is a multi-center retrospective and prospective cohort study, enrolling 1029 patients with HCV and 384 patients with HBV who were histologically diagnosed by liver biopsy.
Journal ArticleDOI

The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection

TL;DR: In this article , the authors compared HCC risk prediction models in patients with chronic hepatitis B infection reported to date to confirm variables used and specificity between each model to determine an appropriate risk prediction method.
Journal ArticleDOI

Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection

TL;DR: For patients who underwent curative resection for HBV-related HCC, TDF treatment had a significantly better overall survival and better protection of liver function, but no difference in the incidences of HCC recurrence than ETV treatment.
References
More filters
Journal ArticleDOI

Management of hepatocellular carcinoma.

TL;DR: The prevention of Cirrhosis can prevent the development of HCC and progression from chronic HCV infection to advanced fibrosis or cirrhosis may be prevented in 40% of patients who are sustained responders to new antiviral strategies, such as pegylated interferon and ribavirin.
Journal ArticleDOI

AASLD guidelines for the treatment of hepatocellular carcinoma

TL;DR: This paper aims to demonstrate the efforts towards in-situ applicability of EMMARM, as to provide real-time information about concrete mechanical properties such as E-modulus and compressive strength.
Journal ArticleDOI

Chronic hepatitis B: Update 2009

TL;DR: The 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines for Management of Chronic Hepatitis B is now posted online at www.aasld.org, and the recommendation for first-line oral antiviral medications has been changed to tenofovir or entecavir, and adefovir has been moved to second-line Oral antiviral medication.
Journal ArticleDOI

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

TL;DR: More efficacious treatments, mass immunization programs, and safe injection techniques are essential for eliminating HBV infection and reducing global HBV‐related morbidity and mortality.
Related Papers (5)

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

Devin Razavi-Shearer, +195 more